BridgeMD
New treatment option for Opioid Use Disorder
Official title Longitudinal Neural Fingerprinting of Opioid-use Trajectories
ClinicalTrials.gov ID: NCT06207162
What this study is testing
- What it's testing
- This project aims to collect a densely sampled neuroimaging dataset among individuals receiving medications for opioid use disorder (MOUD). MOUD is multiphasic, comprised of medication induction, stabilization, ongoing treatment, and eventual dis-continuation phases.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 50
You may be able to join if
- within the first 6 months of methadone treatment for OUD and on a stable dose of methadone
- eligibility for MRI scanning
- willing to commit to longitudinal study visits
You likely can't join if
- current psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5
- current co-occurring severe substance-use disorders (excluding nicotine and opioids), as assessed during screening with the SCID-5
- current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer...
- severe cognitive impairment (determined through consent process conducted by trained clinical research staff and during consent quiz or as indicated...
- Past or present history of intellectual disability or developmental disorder
- Neurological disease (including seizures or epilepsy) as assessed by self-report and by consulting clinic records
See the full eligibility criteria
- within the first 6 months of methadone treatment for OUD and on a stable dose of methadone
- eligibility for MRI scanning
- willing to commit to longitudinal study visits
- current psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5
- current co-occurring severe substance-use disorders (excluding nicotine and opioids), as assessed during screening with the SCID-5
- current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer, and SOWS assessment (these individuals will be allowed to enroll at a...
- severe cognitive impairment (determined through consent process conducted by trained clinical research staff and during consent quiz or as indicated by a PROMIS Cognitive Function t-score \<30 (i.e., score indicating...
- Past or present history of intellectual disability or developmental disorder
- Neurological disease (including seizures or epilepsy) as assessed by self-report and by consulting clinic records
- Head trauma with loss of consciousness of more than 30 minutes
- Organ dysfunction or any unstable or untreated medical conditions that may alter cerebral function or interfere with study participation
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 50 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.